News: Repros Therapeutics Inc. (RPRX.O)

RPRX.O on Consolidated Issue listed on NASDAQ Global Market

0.65USD
18 Dec 2009
Price Change (% chg)

$-0.04 (-5.80%)
Prev Close
$0.69
Open
$0.70
Day's High
$0.71
Day's Low
$0.65
Volume
425,497
Avg. Vol
369,973
52-wk High
$13.94
52-wk Low
$0.65

view news for:
Select another date:

Mon, Nov 9 2009

UPDATE 1-Repros posts wider-than-expected Q3 loss

Nov 9 (Reuters) - Cash-strapped Repros Therapeutics Inc reported a wider-than-expected quarterly loss, sending its shares down about 25 percent in pre-market trade.

Continue Reading

UPDATE 1-Repros amends agreement over Proellex license

NEW YORK, Oct 28 (Reuters) - Repros Therapeutics Inc signed an amendment with the National Institutes of Health (NIH) to its license for Proellex, the company's experimental drug for uterine fibroids on hold for safety reasons.

UPDATE 1-Repros, Targacept to offer shares at discount

Oct 8 (Reuters) - Shares of Repros Therapeutics Inc and Targacept Inc fell sharply, after the companies said they plan to raise money by selling shares at a discount.

UPDATE 1-Repros' testosterone drug shows promise, shares soar

(Adds analyst comment, details; updates share movement)

Repros' testosterone drug successful in small study, shares soar

Oct 7 (Reuters) - Repros Therapeutics Inc said its experimental drug Androxal restored normal sperm count while increasing testosterone levels in an exploratory study, sending its shares up nearly three-fold.

Repros shares down, FDA asks for more data

NEW YORK (Reuters) - Shares of Repros Therapeutics fell 19 percent to 88 cents in premarket trading on Tuesday, after the company said the Food and Drug Administration asked for additional data on the company's lead drug Proellex to resolve the clinical hold placed on it.

UPDATE 1-Repros says FDA asks for more data on lead drug

* Says new development requirements beyond its abilities

HEADLINE STOCKS-Some U.S. stocks on the move on Aug 17

(Updates to afternoon trading, adds Atlas Pipeline and Align/Danaher)

UPDATE 2-Repros Therapeutics runs out of cash, may go bankrupt

* Says doesn't have enough cash to fund ongoing operations

HEADLINE STOCKS-Some U.S. stocks on the move on Aug 17

(Updates to after the open, adds Bank of America, Illinois Tool Works, BJ's, Rosetta Stone, BioSante and Corrections Corp)

Select another date:

Market Views

» More RPRX.O Market Views

Press Releases

view news for: